Subtitle: Market Intelligence for Lysosomal Trafficking Modulators, IGF2 Clearance Pathways, and Large Multi-Domain Receptor Biology.
Molecular Features of IGF2R/CD222
IGF2R (also known as CI-MPR, CD222) is a 250 kDa multi-domain glycoprotein comprising 15 extracellular domains. It contains three Mannose-6-Phosphate Receptor Homology (MRH) domains (MRH1-3), a specific IGF2-binding site on Domain 11, and multiple M6P-binding sites on Domains 3,5,7,9. Key single-nucleotide variants include rs8191704, rs8191746, and rs8191753 (dbSNP), which may affect receptor trafficking or ligand affinity.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for IGF2R/CD222 drug discovery:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen (Full ECD) | IGF2R ECD-Fc Fusion (Domains 1-15) Human, HEK293 Expressed. High Purity (>95%), Endotoxin <1 EU/µg. Theoretical MW ~240 kDa. Sequence Verified. |
View IGF2R Products |
| Antigen (Domain 11) | IGF2R Domain 11-Fc (IGF2 Binding Site) For selective ligand binding assays. Sequence Verified. |
View IGF2R Products |
| Gene Delivery | IGF2R Full-Length ORF Lentivirus CMV promoter, Puromycin selection. Titer >10^7 TU/mL. For stable cell line generation. |
View IGF2R Products |
| Benchmark Ab | Anti-IGF2R Benchmark Antibody Recombinant monoclonal for flow cytometry and IHC validation. |
View IGF2R Products |
| Validator | IGF2R siRNA Set (3x sequence-specific) For knockdown verification and specificity controls. |
View IGF2R Products |
| Related Target: IGF2 | IGF2 (Ligand) For competition binding and clearance assays. Native folding verified. |
View IGF2 Products |
| Related Target: IGF1R | IGF1R (Signaling Receptor) Counter-screening for ligand selectivity (IGF2 binds both). |
View IGF1R Products |
| Related Target: M6PR | M6PR (CD-M6PR) Cation-dependent M6P receptor for comparative lysosomal trafficking studies. |
View M6PR Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Rapid Internalization Validation (ADC/LYTAC) | High-purity HEK293 expressed ECD-Fc with native glycosylation for endocytosis tracking; full-length lentivirus cell lines for pH-sensitive trafficking assays. |
| Receptor Family Cross-Reactivity | Homolog panel proteins (IGF1R, IR) strictly verified by mass spec for counter-screening. |
| Multi-domain Ligand Selectivity (IGF2 vs. M6P) | Domain-specific ECD truncants (Domain 11 for IGF2; Domains 3/5/7/9 for M6P). Sequence verified for epitope mapping. |
| Large Protein Aggregation/Instability | HEK293 expressed with native glycosylation. Endotoxin <1 EU/µg. High purity (>95%) by SEC-HPLC. |
| Lack of Controls | Clinical Benchmark Antibodies and negative control proteins (domain-deleted variants) included. |
| False Positives in Binding Assays | Validated siRNA set included; negative control proteins available for specificity checks. |
| Cross-species Preclinical Evaluation | Human/Mouse/Cynomolgus IGF2R orthologs available with sequence alignment verification. |
Live IGF2R/CD222 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
IGF2R (CD222) represents a paradoxical yet high-value therapeutic node. While functioning canonically as a tumor suppressor through IGF2 clearance and lysosomal trafficking, selective overexpression in hepatocellular carcinoma and specific breast cancer subtypes has positioned it as an emerging ADC target. Simultaneously, the biopharma industry is leveraging its exceptional endocytic capacity for lysosomal enzyme replacement therapies (ERT) targeting rare genetic disorders and for innovative lysosome-targeting chimeras (LYTACs). The current R&D trajectory indicates a bifurcation: first-generation modalities exploit IGF2R's rapid internalization kinetics for cytotoxic payload delivery in oncology, while next-generation programs focus on modulating trafficking efficiency to treat lysosomal storage diseases. As the field advances, critical differentiation will require precise domain-selective binding assays to distinguish between the IGF2-binding site (Domain 11) and mannose-6-phosphate recognition domains.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| ADC | Oncology-focused Biotechs, Academic Consortia | Solid Tumors (HCC, Breast Cancer) | Internalization Efficiency Assay (Full-length Lentivirus cell lines; high-purity ECD-Fc for trafficking measurement) |
| LYTAC / Degrader | Emerging Startups | Oncology / Autoimmune | Lysosomal Trafficking (Physiologically active ECD; pH-dependent binding kinetics) |
| Bispecific/Biologics (IGF2 blockade) | Metabolic Disease Divisions | Overgrowth Syndromes, Cancer Prevention | Domain 11 Selective Binding (Domain 11-specific ECD truncants to avoid M6P cross-reactivity) |
| ERT / Recombinant Enzyme | Sanofi, Takeda; Rare Disease Specialists | Lysosomal Storage Diseases (MPS, Pompe) | M6P Affinity Validation (Native glycosylated receptors; M6P-domain proteins; cross-species orthologs) |
| Gene Therapy (Functional Restoration) | Academic Medical Centers | Cancers with IGF2R Loss of Heterozygosity | Expression & Trafficking Restoration Assay (Full-length ORF Lentivirus for functional validation) |